Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Recruiting
Phase 2
Interventional Study
Chronic Graft-versus-host Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 21 (estimated)
- Sponsor
- Navy General Hospital, Beijing · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Written informed consent
* Male
* not pregnant female
* patients \<65 years old
* Diagnosis of cGVHD steroid refractory (no response after Prednisone ≥1mg/kg ) or steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon steroid taper)
* Patient intoleran…
Contacts